[Glucobay in the therapy of patients with non-insulin-dependent diabetes mellitus].
The article focuses on the action of a new sugar-lowering drug preparation glucobai (acarbose) in 47 patients with non-insulin-dependent diabetes mellitus (NIDM). The drug was prescribed at a dose of 150-300 mg daily with meal. A marked sugar-lowering effect was manifested by reduction of the level of postprandial hyperglycemia, glycosylated hemoglobin, fructosamine, body mass of the patients. The results obtained permit recommending glucobai (acarbose) as a sugar-lowering drug in NIDM patients.
P M
PM
Bodnar
L O
LO
Kononenko
D020909:Acarbose; D000284:Administration, Oral; D000328:Adult; D002908:Chronic Disease; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D014312:Trisaccharides / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D014312:Trisaccharides; D020909:Acarbose